COMPANY PROFILE

Genis

Explore full profile

Pioneering the development of therapeutic chitin derivatives

Siglufjörður, IcelandFounded 2005Biotech & Life Sciences

Valuation $100–250M Last recorded · 2022

Revenue <$1M Latest reported FY

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Genis

Genis.is operates in the health and wellness sector, focusing on the development and sale of innovative health supplements. The company primarily serves health-conscious consumers looking to improve cognitive function and sleep quality. Genis.is leverages scientific research to formulate its products, ensuring efficacy and safety for its users. The business model is direct-to-consumer, with products available for purchase through their online platform. Revenue is generated through the sale of these health supplements, which are marketed based on their scientifically-backed benefits. The company operates in multiple European markets, including Germany, the United Kingdom, and Iceland, indicating a broad geographical reach and a diverse customer base.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2005
Headquarters: Siglufjörður, Iceland
Employees: 33
Open positions: None listed
Dealroom signal: 47.2/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Dietary Supplements, Biotechnology, Superfood, Biotech and Pharma, Hard Tech, Horizon Europe, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

7 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VC✓Equity / VC	Dec 2022	$17M	$68M	Andri Sveinsson · Yanu · Sigþór Sigmarsson · TM tryggingar	↗
GRANT✓Other financing	Jan 2020	$220	—	Icelandic Centre for Research	—

Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin	Profit	Margin
2026
2025
2024
2023
2022
2021
2020		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Genis website traffic

Latest recorded traffic for Genis is 20 monthly website visits, down 98.2% over the last three months. Genis's team grew 3.1% over the past year.

Latest monthly visits20 3-month web change-98.2% 1-year team growth+3.1%

Monthly website visitsFeb 2016–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ABAxol BioscienceSells live human cell cultures and provides services such as genome editing to researchers	Cambridge, United Kingdom	Acquired	61	$13M	$13M
JUJunhetangJunhetang operates traditional Chinese medicine clinics	China	Operational
APAkkadeas PharmaBiotech & Life Sciences	Milan, Italy	Operational
SCSancilio and CompanySancilio and Company develops biopharmaceutical supplements and products.	Riviera Beach, United States	Operational
NONorsaPharmaProduces, develops, and distributes special food, diet supplements, and pharmaceuticals for people with rare medical conditions and unusual nutrition needs	Kraków, Poland	Operational
SPSprout PharmaceuticalsPharmaceutical company that develops products for the treatment of female sexual dysfunction	Raleigh, United States	Acquired
VIVibrantDrug-free alternative for sdult patients with chronic idiopathic constipation	Newton, United States	Operational
SASanifitDevelops treatments for cardiovascular diseases	Palma, Spain	Acquired